Cytokinetics, Inc. (CYTK)
56.07
-0.09
(-0.16%)
USD |
NASDAQ |
Nov 13, 16:00
56.15
+0.08
(+0.14%)
After-Hours: 19:59
Cytokinetics Enterprise Value : 7.958B for Nov. 12, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 12, 2026 | 7.958B |
| November 11, 2026 | 8.288B |
| November 10, 2026 | 7.961B |
| November 09, 2026 | 7.816B |
| November 06, 2026 | 7.614B |
| November 05, 2026 | 7.873B |
| November 04, 2026 | 8.994B |
| November 03, 2026 | 8.814B |
| November 02, 2026 | 8.775B |
| October 30, 2026 | 8.909B |
| October 29, 2026 | 8.953B |
| October 28, 2026 | 8.671B |
| October 27, 2026 | 8.704B |
| October 26, 2026 | 8.594B |
| October 23, 2026 | 8.664B |
| October 22, 2026 | 8.817B |
| October 21, 2026 | 8.891B |
| October 20, 2026 | 9.043B |
| October 19, 2026 | 8.862B |
| October 16, 2026 | 8.764B |
| October 15, 2026 | 9.038B |
| October 14, 2026 | 8.970B |
| October 13, 2026 | 8.718B |
| October 12, 2026 | 8.881B |
| October 09, 2026 | 8.898B |
| Date | Value |
|---|---|
| October 08, 2026 | 8.772B |
| October 07, 2026 | 8.649B |
| October 06, 2026 | 8.681B |
| October 05, 2026 | 8.869B |
| October 02, 2026 | 9.272B |
| October 01, 2026 | 9.275B |
| September 30, 2026 | 9.315B |
| September 29, 2026 | 9.210B |
| September 28, 2026 | 9.282B |
| September 25, 2026 | 9.074B |
| September 24, 2026 | 9.213B |
| September 23, 2026 | 9.234B |
| September 22, 2026 | 9.481B |
| September 21, 2026 | 9.477B |
| September 18, 2026 | 9.646B |
| September 17, 2026 | 9.804B |
| September 16, 2026 | 9.730B |
| September 15, 2026 | 9.719B |
| September 14, 2026 | 10.16B |
| September 11, 2026 | 10.34B |
| September 10, 2026 | 10.32B |
| September 09, 2026 | 10.39B |
| September 08, 2026 | 10.56B |
| September 04, 2026 | 10.19B |
| September 03, 2026 | 10.36B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| BridgeBio Pharma, Inc. | 18.15B |
| Alnylam Pharmaceuticals, Inc. | 20.38B |
| BioMarin Pharmaceutical, Inc. | 14.45B |
| Exelixis, Inc. | 16.36B |
| Ionis Pharmaceuticals, Inc. | 4.834B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -190.07M |
| Revenue (Quarterly) | 47.56M |
| Total Expenses (Quarterly) | 237.63M |
| EPS Diluted (Quarterly) | -1.367 |
| Gross Profit Margin (Quarterly) | 87.67% |
| Profit Margin (Quarterly) | -399.7% |
| Earnings Yield | -10.77% |
| Normalized Earnings Yield | -10.92 |